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A B S T R A C T
Background
Heavy menstrual bleeding (HMB) is an important cause of ill health in pre menopausal women. Medical therapy, with the avoidance
of possibly unnecessary surgery is an attractive treatment option, but there is considerable variation in practice and uncertainty about
the most effective therapy. Danazol is a synthetic steroid with anti-oestrogenic and anti progestogenic activity, and weak androgenic
properties. Danazol suppresses oestrogen and progesterone receptors in the endometrium, leading to endometrial atrophy (thinning of
the lining of the uterus) and reduced menstrual loss and to amenorrhoea in some women.
Objectives
To determine the effectiveness and tolerability of danazol when used for heavy menstrual bleeding in women of reproductive years.
Search strategy
We searched the Menstrual Disorders and Subfertility Group’s Specialised Register of controlled trials (6 Nov 2001). We also searched
the Cochrane Controlled Trials Register (Cochrane Library, Issue 3, 2001), MEDLINE (1966 to Oct 2001), EMBASE (1980 to Oct
2001), Current Contents (1993 to Oct 2001), CINAHL (1982 to Sept 2001), and the National Research Register (Issue 3, 2001).
Attempts were also made to identify trials from citation lists of included trials and relevant review articles. In most cases the first author
of each included trial was contacted for unpublished additional information.
Selection criteria
Randomised controlled trials of danazol versus placebo, any other medical (non-surgical) therapy or danazol in different dosages for
heavy menstrual bleeding in women of reproductive age with regular HMB measured either subjectively or objectively. Trials that
included women with post menopausal bleeding, intermenstrual bleeding and pathological causes of heavy menstrual bleeding were
excluded.
Data collection and analysis
Nine RCTs, with 353 women, were identified that fulfilled the inclusion criteria for this review. Quality assessment and data extraction
were performed independently by two reviewers. The main outcomes were menstrual blood loss, the number of women experiencing
adverse effects, weight gain, withdrawals due to adverse effects and dysmenorrhoea. If data could not be extracted in a form suitable
for meta-analysis, they were presented in a descriptive format.
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Main results
Most data were not in a form suitable for meta analysis, and the results are based on a small number of trials, all of which are under-
powered. Danazol appears to be more effective than placebo, progestogens, NSAIDs and the OCP at reducing MBL, but confidence
intervals were wide. Treatment with danazol caused more adverse events than NSAIDs (OR 7.0; 95% CI 1.7, 28.2) and progestogens
(OR 4.05, 95% CI 1.6, 10.2), but this did not appear to affect adherence to treatment. Danazol was shown to significantly lower
the duration of menses when compared with NSAIDs (WMD -1.0; 95% CI -1.8, -0.3) and a progesterone releasing IUD (WMD
-6.0; 95% CI -7.3, -4.8). There were no randomised trials comparing danazol with tranexamic acid or the levonorgestrel-releasing
intrauterine system.
Authors’ conclusions
Danazol appears to be an effective treatment for heavy menstrual bleeding compared to other medical treatments, though it is uncertain
whether it is acceptable to women. The use of danazol may be limited by its side effect profile, its acceptability to women and the need
for continuing treatment. Overall no strong recommendations can be made due to the small number of trials, and the small sample
sizes of the included trials.
P L A I N L A N G U A G E S U M M A R Y
Danazol is an effective treatment for the reduction of heavy menstrual bleeding, but the adverse effects may be unacceptable to women
Options to help avoid surgery can be important for many women who are having problems with heavy menstrual bleeding. One of the
drug options is danazol. Danazol suppresses the hormones that increase the endometrium (the lining of the uterus that is shed during
menstruation). However, danazol can also produce male characteristics and some menopause-like symptoms, as well as weight gain and
acne. The review found that although danazol is effective at reducing menstrual blood loss there are not enough trials to show whether
this treatment is acceptable to women with heavy menstrual bleeding.
B A C K G R O U N D
Heavy menstrual bleeding (menorrhagia) can have a significant
impact on women’s lives. In the UK, one in 20 women aged 30-49
consult their general practitioner each year with heavy menstrual
bleeding (Vessey 1992) and it accounts for 12% of all gynaeco-
logical referrals (Bradlow 1992). Once referred to a gynaecologist,
surgical intervention is highly likely (Coulter 1991).
Heavy menstrual bleeding (HMB) or menorrhagia is clinically
defined as greater than or equal to 80 ml blood loss per menstrual
cycle (Hallberg 1966; Cole 1971). It is, however, the woman’s
perception of her ownmenstrual loss which is the key determinant
in a referral and, indeed, subsequent treatment. The main aim of
the treatment of menorrhagia is to reduce blood loss in order to
improve quality of life and prevent anaemia.
Many factors can cause HMB for example coagulation disorders,
endocrine disorders, uterine abnormalities andother pelvic pathol-
ogy. These disorders should be excluded before decisions are made
about treatment as theymay require different management. How-
ever, in most cases, there is no pathological cause of the heavy
bleeding, and the condition is labelled dysfunctional uterine bleed-
ing (EHCB 1995). Eighty percent of women treated for menor-
rhagia have no uterine abnormality and over a third of the women
undergoing hysterectomies for HMB have a normal uterus re-
moved (Gath 1982; Clarke 1995). Although patient satisfaction
with hysterectomies is high (Coulter 1994), there are complica-
tions and occasional death associated with hysterectomy (Dicker
1982). Complications are more likely when the hysterectomy is
performed by the open abdominal route, as is usually the case
(Hospital 1995). Effective medical therapy, that avoids unneces-
sary surgery, is therefore an attractive alternative.
A wide variety of medications are available to reduce HMB but
their effectiveness has been questioned (Coulter 1995). The aim
of this review is to see if danazol is an effective therapy for HMB.
Danazol is chemically derived from testosterone (a naturally oc-
curring hormone). It inhibits ovulation and reduces oestrogen lev-
els. It also causes endometrial atrophy (thinning of the lining of
the uterus), reduced menstrual loss and leads to amenorrhoea (ab-
sence of periods) in some women (Chimbira 1980b). Danazol has
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a dramatic effect on increasing haemoglobin and serum ferritin
levels and may therefore be valuable in women who need effective
therapy to stop very heavy bleeding and restore their haemoglobin
and iron status to normal (Ford 1994; Chimbira 1979). Danazol
has androgenic properties (a tendency to cause male characteris-
tics) which may result in acne, seborrhoea (greasy skin) and hir-
sutism (excessive hair growth). Other side effects include weight
gain, irritability, musculoskeletal pains, hot flushes and breast at-
rophy (loss of breast tissue). Longer term treatment with danazol
may cause liver effects (including benign hepatic adenomas) in
some women.
O B J E C T I V E S
To determine the effectiveness and tolerability of danazol when
given for heavy menstrual bleeding in women of reproductive
years.
We wished to investigate:
1. Whether treatment with danazol is more effective than placebo
in reducing heavy menstrual blood loss.
2. Whether treatment with danazol is more effective than other
medical therapies (antifibrinolytics, NSAIDs, progestogens) in re-
ducing heavy menstrual blood loss.
3. If effective, what is the optimum dosage of danazol.
4. Whether treatment with danazol leads to an improved quality
of life for women with heavy menstrual blood loss.
5. Whether women tolerate treatment with danazol and find it an
acceptable treatment.
R E S U L T S
Overall nine studies compared the use of danazol with placebo,
othermedical treatments or different doses of danazol for the treat-
ment of heavy menstrual bleeding. The studies contained a total
of 353 participants.
DANAZOL VS. PLACEBO
One study with 66 participants compared danazol 200 mg once
daily with a matched placebo once daily for three months of treat-
ment (Lamb 1987).
Menstrual blood loss (objective/subjective)
This study did not assess objective MBL, and subjective MBL was
assessed using an unidentified scoring system. It was not possible
to include data for the menstrual blood loss scores, as the type
of scoring system used and the figures were poorly reported in
the paper. The authors report no significant differences in blood
loss scores for the placebo group when comparing before and after
treatment scores. A significant difference in blood loss scores was
reported for the danazol group compared to the pre-treatment
scores, but it is unclear how this was calculated.
Duration of menses
The data for duration of menses could not be included in this
review as the figures were inadequately reported in the paper. The
author reportednodifference in durationofmenses for the placebo
group comparing pre and post treatment figures. A significant
difference in duration of menses was reported for the danazol
group (when comparing before and after treatment figures), but
the authors do not indicate how this was calculated.
Withdrawals due to side effects
The number of withdrawals due to side effects during the inter-
vention did not significantly differ between the two groups (OR
2.06, 95% CI 0.18, 23.94).
Body weight
The trial reported data on the mean body weight for each group.
After three months treatment the mean weight (kg) of the danazol
group was significantly greater than that of the placebo group
(WMD 6.70, 95% CI 0.98, 12.42).
DANAZOL VS. PROGESTOGENS
Five of the included studies involving a total of 131 women com-
pared 200 mg danazol with a progestogen. For four of the studies
the comparison intervention was norethisterone, and in one study
the progestogen was medroxyprogesterone acetate.
Menstrual blood loss (objective/subjective)
Four of the studies comparing danazol with a progestogen reported
data on MBL. In two trials MBL was measured objectively using
the alkaline haematin method. One small parallel trial comparing
danazol with norethindrone in themeta analysis (n=37) showedno
significant difference between the two groups for menstrual blood
loss after treatment (WMD -35.60 , 95% CI -102.20, 31.00)
(Higham 1993). The other trial reporting objectively measured
MBL, contained data which was not reported in a form suitable
for pooling. This trial reportedMBL asmedians and ranges, rather
than means and standard deviations and is included as descriptive
data in the Other Data section (Cameron 1987). In this trial the
groups were not comparable at baseline, and the study compared
MBLafter treatment toMBLat baseline for the different treatment
groups. There was no significant difference between the before
and after treatment values for the progestogen group (p>0.05),
where as MBL after treatment was significantly lower than that at
baseline for the danazol group (p<0.05) (Cameron 1987).
Two studies comparing danazol with a progestogen reported sub-
jective measures of MBL. Both are included as descriptive data
in the other data section due to skewing of the data in one
(Dunphy 1998) and use of a non-standard bleeding scale in the
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other (Bonduelle 1991). One trial used the pictorial chart method
described by Higham (1990) to record monthly blood loss and
reported that MBL after three months treatment was significantly
lower in the danazol group compared to the medroxyprogesterone
acetate group (p=0.0128) (Dunphy 1998). The other study used a
seven point scoring system where daily bleeding scores were com-
bined to give a score for each menstrual period. The trial com-
pared bleeding scores after three months treatment and showed a
significant difference between the two groups in favour of danazol
(p<0.05).
One study (n=18) included the outcome of MBL three months
after the intervention. The trial showed that MBL (assessed by the
pictorial chart method) was significantly lower in the progestogen
group three months after treatment was stopped (WMD 203.00,
95%CI 25.65, 380.35) (Dunphy 1998).
Side effects
Four trials reported the number of women in each of the two
treatment groups experiencing side effects. The four studies in the
meta analysis showed that significantly more women in the dana-
zol group experienced side effects compared to the progestogen
group (OR 4.05, 95% CI 1.61, 10.21) (Bonduelle 1991; Buyru
1995; Dunphy 1998; Higham 1993). Commonly reported side
effects for danazol treatment included acne,weight gain, headache,
nausea and tiredness. One study found that adverse effects were
reported with a similar frequency and were of a similar nature
in both treatment groups (Bonduelle 1991). Commonly reported
side effects in this study were weight gain, bloating, gastro-intesti-
nal symptoms, skin changes, lethargy, depression and reduced con-
centration. Buyru 1995 found that headaches and muscle cramps
were reported with similar frequency in both groups, but the dana-
zol group also complained of weight gain, acne, nausea and inter-
menstrual bleeding. The Higham (1993) study found that both
groups reported the adverse effects of muscle cramps and depres-
sion with similar frequency. In this study, other commonly re-
ported side effects amongst the danazol group included headache,
weight gain, nausea and vomiting and acne, where as other ad-
verse effects reported amongst the progestogen group were pre-
menstrual tension symptoms (Higham 1993).
Withdrawals due to side effects
Four trials comparing danazol with a progestogen reported the
number of withdrawals due to side effects. Pooling of data from
these studies showed that there was no significant difference be-
tween the two groups in terms of withdrawals due to side effects
(OR 1.67, 95% CI 0.53, 5.23).
Duration of menses
Four studies comparing danazol with a progestogen assessed the
duration of menses. The Chi square test for heterogeneity showed
there is significant heterogeneity within the comparison (19.52,
df=3, p=0.0002). To consider this heterogeneity, the datawas anal-
ysed using a random effects model to take into account the vari-
ability between the studies when calculating the summary statistic.
Pooling of data from these trials shows that there was no signifi-
cant difference between the groups in the duration of menses after
treatment (WMD -0.74, 95%CI -2.31, 0.82).
Dysmenorrhoea
One of the studies comparing danazol with a progestogen reported
this outcome (Bonduelle 1991). Abdominal pain and backache
were assessed using a three point scoring system. The study com-
pared before and after treatment scores for both measures of pain
for the two groups. For the danazol group there was no significant
difference in the before and after treatment scores on either of
these measures of dysmenorrhoea (p>0.05). The post treatment
backache score was significantly lower than that at baseline for
the norethisterone group (p<0.05), but there was no significant
difference in the before and after treatment abdominal pain scores
(p>0.05). This trial was included as descriptive data in the other
data section due to the use of a non standard pain scale.
Weight gain
Three studies comparing danazol with a progestogen reported
weight gain as an outcome measure. One trial reported weight
gain as mean weight gain, and showed that the mean weight gain
was significantly higher in the danazol group (WMD 2.80, 95%
CI 1.60, 4.00) (Dunphy 1998). One study reported the number
of women with a weight gain of >2kg and the another reported
the number of women with weight gain of >3kg. For weight gain
as a dichotomous variable there was no significant difference be-
tween the danazol and progestogen groups. Where the number
of women with weight gain >2kg was assessed the OR was 2.86
(95% CI 0.48, 17.11) (Higham 1993) and where the numbers
with weight gain >3kg was reported the OR was 5.57 (95% CI
0.48, 64.09) (Bonduelle 1991). But the reported results are im-
precise with wide confidence intervals.
Efficacy of intervention
Three studies included this outcome. One study assessed this ob-
jectively, reporting the number in each group with MBL of <80
ml at the end of the intervention, and the other two studies as-
sessed efficacy subjectively. The study assessing efficacy objectively
showed a significant difference in favour of danazol. Significantly
more women in the danazol group had a MBL of less than 80
ml at the end of the intervention (OR 7.20 95% CI 1.28, 40.37)
(Higham 1993).
For subjective efficacy of medication, where efficacy was measured
as the number of women rating the treatment as highly or mod-
erately effective, subjective efficacy was significantly better after
danazol treatment than after norethisterone (OR 4.33, 95% CI
1.09, 17.17) (Higham 1993). Where efficacy was assessed by the
numbers rating their MBL as none or moderate, there was no sig-
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nificant difference between the two groups (OR 5.83, 95% CI
0.70, 48.87) (Bonduelle 1991).
DANAZOL VS. NSAIDS
Three studies compared danazol with a NSAID for the treatment
of heavy menstrual bleeding. All three studies compared danazol
with mefenamic acid, but one trial also used naproxen as a com-
parison intervention.
Menstrual blood loss (objective/subjective)
All three studies reported this outcome, and all assessed MBL us-
ing the alkaline haematin method. One small parallel trial (n=39)
in the meta-analysis showed that mean MBL after two months
treatment was significantly lower in the danazol group compared
to the mefenamic acid group (WMD -96.70, 95% CI -138.80,
-54.60) (Dockeray 1989). Two other trials are included as de-
scriptive data in the other data section as one reported MBL in a
form unsuitable for inclusion in the meta analysis and in the other
the data showed significant skewness. One trial included in the
other data section, compared danazol with mefenamic acid and
reportedMBL as medians and ranges. In this trial the groups were
not comparable at baseline and the study compared MBL after
treatment to MBL at baseline for the different treatment groups,
rather than comparing MBL across the groups. MBL after treat-
ment was significantly lower than that at baseline for the danazol
group (p<0.05), but there was no significant difference between
the before and after treatment MBL values for the mefenamic
acid group (p>0.05) (Cameron 1987). The other trial was a cross-
over trial which compared danazol with both mefenamic acid and
naproxen. When the mean and standard deviation were calculated
from the individual participant data and put into the meta-analy-
sis, meanMBL after twomonths treatment was significantly lower
in the danazol group compared to both the mefenamic acid group
(p=0.001) and the naproxen group (p=0.02) (Fraser 1991). These
figures refer to data prior to participants crossing over to the other
treatment .
Side effects
One studywhich compared danazol withmefenamic acid reported
this outcome. There were significantly more adverse effects in the
danazol group compared to the mefenamic acid group 75% com-
pared to 30% (OR 7.00, 95% CI 1.74, 28.17) (Dockeray 1989).
The mefenamic acid group complained mainly of nausea, vomit-
ing and diarrhoea; the danazol group complained of more serious
adverse effects such as musculoskeletal pains, dizziness, flushes,
acne, behavioural changes, tiredness, breast atrophy, hirsutism and
hoarseness.
Withdrawals due to side effects
None of the studies comparing danazol with a NSAID reported
this outcome.
Duration of menses
Two trials in both of which mefenamic acid was the comparison
intervention assessed this outcome. Pooling of data from these
trials showed the duration of menses was significantly shorter in
the danazol groups after two months of treatment (WMD -1.03;
95% CI -1.78 -0.28).
Dysmenorrhoea
One parallel study reported this outcome. Dysmenorrhoea was as-
sessed in twoways in the study; according to the number of women
in each intervention group who reported an improvement in dys-
menorrhoea after two months treatment, and using a three point
pain scale scoring system. The number reporting an improvement
in dysmenorrhoea showed no significant difference between the
two interventions (OR 1.20; 95% CI 0.20, 7.31). The dysmen-
orrhoea scores showed no significant difference between the two
groups after two months of treatment (p>0.05) (Dockeray 1989).
The data for the dysmenorrhoea scores was included in the Other
Data section due to the use of a non-standard pain scale.
Acceptability of treatment
One study included the outcome of the numbers in each group
unwilling to continue that particular treatment. This small parallel
trial (n=39) compared danazol with mefenamic acid and showed
no significant difference between the two groups with regard to
the number unwilling to continue the treatment (OR 1.11; 95%
CI 0.32, 3.90) (Dockeray 1989).
DANAZOL VS. ORAL CONTRACEPTIVE
One small cross-over study involving 12women compareddanazol
200 mg with an oral contraceptive (ethinyl oestradiol 30ug and
levonorgestrel 150ug) (Fraser 1991). Only the data prior to the
cross-over were included in the analysis.
Menstrual blood loss (objective/subjective)
Blood loss was measured objectively using the alkaline haematin
method. After two months treatment mean MBL for the danazol
group was significantly lower than that for the oral contraceptive
group (p=0.02). The trial was included in the Other Data section
as descriptive data due to skewness of the data.
Other outcomes
The only trial comparing danazol with an oral contraceptive did
not report any other outcome measures.
DANAZOL VS. PROGESTERONE RELEASING IUD
One trial with 14 participants compared danazol with a proges-
terone releasing intrauterine device (releasing 65ug progesterone
daily) for two months treatment.
Menstrual blood loss (objective/subjective)
MBL was measured objectively using the alkaline haematin
method. The study compared MBL after the intervention with
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that at baseline for each of the interventions, rather than making
comparisons between the groups as the groups were not compa-
rable at baseline. For both groups MBL after the intervention was
significantly lower than that at baseline p<0.05 and p<0.01 for the
danazol and progesterone releasing IUD interventions respectively
(Cameron 1987). The trial was included as descriptive data in the
Other Data section as the data was not reported in a form suitable
for inclusion in the meta-analysis.
Duration of menses
The one trial comparing danazol with a progesterone releasing
IUD reported data on the duration of menses after two months
treatment compared with that at baseline for each group. The
results show that the mean duration of menses was significantly
shorter in the danazol group (WMD -6.00; 95%CI -7.25, -4.75).
DANAZOL 200 mg VS. DANAZOL 100 mg
One study involving 32 participants compared danazol 200 mg
with danazol 100mg for the treatment of heavymenstrual bleeding
(Chimbira 1980a).
Menstrual blood loss (objective/subjective)
MBL was reported objectively after three months treatment and
compared with mean MBL at baseline for each group. For both
groups mean MBL after three months treatment was significantly
lower than mean MBL at baseline (p<0.01). There was no sig-
nificant difference between the two groups after three months of
treatment (p=0.2) (Chimbira 1980a). This trial was reported in
the Other Data section as descriptive data as the data showed sig-
nificant skewness.
Duration of menses
The mean duration of menses was included as one of the outcome
measures in the study comparingdanazol 200mgwith danazol 100
mg. The authors reported that the duration of menses after three
months treatment with danazol 200 mg was significantly less than
that at baseline (p<0.01). There was no significant difference in the
duration of menses after three months treatment with danazol 100
mg compared to that at baseline (p>0.05). The trial was reported
as descriptive data in the Other Data section as the figures were
inadequately reported in the paper.
Dysmenorrhoea
The study assessed the outcome of the numbers in each group
reporting an improvement in dysmenorrhoea after three months
treatment. For this outcome there was no significant difference
between the two groups (OR 0.68; 95%CI 0.12, 3.83) (Chimbira
1980a).
Weight gain
The trial comparing danazol 200 mg with danazol 100 mg re-
ported the mean gain in weight for the two groups, danazol 200
mg (mean weight gain 2.3 kg after three months of treatment),
danazol 100 mg (mean of 2.1 kg) (Chimbira 1980a). No standard
deviations were reported in the trial so a WMD could not be cal-
culated.
DANAZOL 200mg VERSUSREDUCINGDOSEDANAZOL
One small parallel trial compared danazol 200 mg with a reducing
dose of danazol for three months treatment. Thirty six women
were involved in this comparison. The reducing dose danazol was
a regime of danazol 200 mg/day for one month, 100 mg/day the
next month and danazol 50 mg/day for the third month.
Menstrual blood loss (objective/subjective)
Mean MBL was measured objectively after three months treat-
ment, and there was no significant difference in mean MBL be-
tween the two groups (WMD 33.50; 95% CI -32.38, 99.38)
(Higham 1993).
Side effects
The number of women in each intervention group experiencing
adverse effects was reported as an outcome measure. For this out-
come there was no significant difference between the two groups
(OR 1.13, 95% CI 0.14, 9.07) (Higham 1993).
Withdrawals due to side effects
The number of withdrawals due to side effects showed no signifi-
cant difference between the danazol 200 mg group and the group
taking a reducing dose of danazol (OR 0.88, 0.15,5.05) (Higham
1993).
Weight gain
The study comparing danazol 200 mg with a reducing dose of
danazol assessed the number of women in each group who had
a weight gain of >2kg after three months treatment. There was
no significant difference between the two groups on this outcome
measure (OR 0.32, 95% CI 0.08, 1.28) (Higham 1993).
Duration of menses
The mean duration of menses for women in the two intervention
groups was assessed after three months treatment. The only trial in
themeta-analysis showedno significant difference between the two
intervention groups (WMD 1.30, 95%CI -0.76, 3.36) (Higham
1993).
Subjective efficacy of intervention
Subjective efficacy was measured as the number of women rating
the treatment as highly ormoderately effective in each of the inter-
vention groups. There was no significant difference between the
two groups after three months of daily treatment (OR 1.18, 95%
CI 0.30, 4.73) (Higham 1993).
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D I S C U S S I O N
The aim of this review was to assess the effectiveness and tolera-
bility of danazol for the treatment of heavy menstrual bleeding.
Despite the fact that danazol has been available for the treatment
of menorrhagia for a considerable length of time, there is a general
lack of well-designed research to evaluate the effectiveness and tol-
erability of this therapy. The results of this review are based on a
small number of trials which are underpowered and with unclear
allocation concealment.
The largest trial had 20 women in each arm. A power calculation
for sample size based on a (alpha)=0.05 and b (beta)=0.80 where
danazol treatment is compared to either progestogen or NSAID
therapy (the most common medical treatments) indicated that
at least 30 women in each arm would be required to show an
acceptable increase in benefit (30%) in the proportion of women
having their menstrual bleeding reverting to normal (<80 mls/
cycle). It was not feasible to consider a benefit of treatment in terms
of the actual quantity of blood loss, mls/cycle, that women find
satisfactory and no data were available to assess satisfaction with
treatment. Therefore, where no differences between interventions
are reported, it may be that the trials are too small to show any
difference.
MENSTRUAL BLOOD LOSS: objective measurement
Danazol was shown to be no more effective than progestogens
at reducing MBL by one trial included in the meta-analysis. If
response to treatment is defined as reduction of menstrual blood
loss to <80 ml/cycle, significantly more women in the danazol
group had theirMBL reduced to below 80ml/cycle. Another trial,
included as descriptive data, suggested that danazol may be more
effective than progestogens at reducing MBL. One limitation of
the studies comparing danazol with a progestogen is that in all
these studies, the progestogen was given in the luteal phase of the
cycle (days 19-26). Progestogens given during the luteal phase of
the cycle in women with ovulatory HMB may increase, rather
than reduce menstrual blood loss (Preston 1995).
Danazol was shown to be more effective at reducing MBL than
mefenamic acid by the one trial included in the meta-analysis and
two other trials. Danazol was also shown to be more effective than
naproxen at reducingMBLby one small trial included in themeta-
analysis. Thus there is consistent evidence that danazol is more
effective than NSAIDs in reducing MBL.
Danazol was shown to be more effective at reducing MBL than
the oral contraceptive pill by one small trial included as Other
Data. The results of one trial included as descriptive data indicate
danazol is no more effective than a progestogen releasing IUD in
reducing MBL.
On the available evidence, a 200 mg daily danazol regime appears
to be no more effective in reducing MBL compared to danazol
100 mg or a reducing dose danazol regimen. There are some lim-
itations to this evidence. The results are based on one trial and
small numbers of participants for all comparisons and the data for
some comparisons are heavily skewed.
It is possible that the differences found were underestimated. Tri-
als were included in this review if women had a subjective com-
plaint of heavy menstrual bleeding and/or if they had objectively
determined heavy menstrual bleeding. In all of the included stud-
ies, participants had a subjective complaint of heavy menstrual
bleeding and in five studies, women had their MBL objectively
measured by the alkaline haematin method. To comply with the
definition of objectively defined menorrhagia, trials would have
to include only women with MBL>80 ml/cycle. However in one
study participants were included if their objectively defined MBL
was>50 ml/cycle (Cameron 1987) and another included women
with a MBL of >60 ml/cycle. Menorrhagia was correctly defined
as objectively determined MBL of >80 ml/cycle in three studies
(Dockeray 1989; Dunphy 1998; Higham 1993).
Many women who seekmedical help for heavymenstrual bleeding
have normal blood loss (Fraser 1984; Haynes 1977) and results
fromoneRCThave suggested that there is little response to therapy
in women with MBL <35 ml (Fraser 1981). Since a proportion
of the study participants with a complaint of heavy menstrual
bleedingmay have had normalmenstrual blood loss, it is likely that
some reported differences between treatment and placebo groups
have been underestimated.
MENSTRUAL BLOOD LOSS: subjective measurement
Whilst the alkaline haematin extraction method is the most ac-
curate method for assessment of blood loss and is used as the
standard, a woman’s own perception of her MBL is important in
the evaluation of effectiveness of treatment on MBL. Therefore a
woman’s subjective assessment is an important outcome measure.
Three studies recorded MBL according to subjective measures.
One trial compared danazol 200 mg daily and a placebo and the
authors reported that danazol was significantly more effective after
two months treatment. Danazol was shown to be significantly
more effective than progestogens at reducing MBL by one study
which used a pictorial bleeding chart method to assess MBL and
by one study which used a bleeding intensity score to assess MBL.
The subjective assessment of MBL is an important outcome mea-
sure, as most diagnoses and interventions for heavy menstrual
bleeding are based on clinical evidence, in the absence of objec-
tively determined heavy menstrual bleeding. It is therefore impor-
tant in practice that any intervention results in a significant im-
provement in the woman’s own perceived cyclical loss.
MENSTRUAL BLOOD LOSS AFTER CESSATION OF
THERAPY
It has been reported that danazol has a significant ’carry-over’
effect and many women have reducedMBL for up to four months
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after cessation of therapy (Shaw 1994), suggesting that danazol
could be used intermittently. Danazol might be more acceptable
in clinical use if it could be effectively used intermittently. There
are no studies assessing intermittent danazol use for HMB, but
two of the included studies (Dunphy 1998; Lamb 1987) assessed
whether danazol has a significant ’carry-over’ effect. Lamb (1987)
reported that a reduction in blood loss score was maintained for
four months after treatment ceased, but insufficient information
was provided for these data to be included in the review. This
finding was not confirmed in one study which compared danazol
with a progestogen, and found there to be no significant carry-over
effect of danazol 3 months after treatment was stopped (Dunphy
1998).
As danazol has a rapid and significant effect on increasing haemo-
globin and serum ferritin (Chimbira 1979; Ford 1994), it may be
valuable in women who need a highly effective short term treat-
ment to stop very heavy bleeding and restore their haemoglobin
and iron status to normal. One of the potential short term uses
of danazol is to use it intermittently, however there is currently
insufficient evidence to assess whether danazol can be effectively
used on an intermittent basis.
ADVERSE EVENTS
There were no significant differences in reported adverse effects
with danazol 200 mg in comparison with a reducing dose dana-
zol. No data are available for whether women treated with danazol
experience more adverse effects than those treated with the oral
contraceptive or a progestogen releasing IUD. However, women
treated with danazol experienced significantly more adverse effects
than those treated with a progestogen and those treated with mefe-
namic acid.
Danazol has weak androgenic properties, and hence can cause side
effects related to this. These side effects spontaneously resolve after
cessation of treatment. None of the included trials reported data
on numbers experiencing specific adverse events in a suitable form
for inclusion in this review, but commonly reported side effects
for danazol treatment included acne, weight gain, headache, nau-
sea and tiredness. One study comparing danazol with mefenamic
acid, reported that women in the mefenamic acid group experi-
enced mostly gastrointestinal side effects such as nausea/vomiting
and diarrhoea, whereas women in the danazol group experienced
more serious side effects such as musculoskeletal pains, flushes,
behavioural changes, lethargy, and androgenic effects such as acne,
breast atrophy, hirsutism and hoarseness (Dockeray 1989).
Women using danazol for heavy menstrual bleeding are likely to
require long term treatment, so any adverse events which affect
adherence to treatment or treatment safety are particularly impor-
tant. One study reported that for the women treated with dana-
zol, the side effects of breast atrophy, hirsutism and hoarseness
did not develop until the second month of treatment (Dockeray
1989). As the studies included in this review all involved two to
three months treatment, data on the side effect profile of danazol
for longer term treatment with danazol would be useful. A longer
period of treatment would enable the longer term liver effects of
danazol to be assessed. These potential liver effects may be an im-
portant factor limiting the long term use of danazol and they have
not been evaluated by any of the studies.
WEIGHT GAIN
Weight gain is one of the androgenic side effects of danazol which
may limit its use (Irvine 1999), and is therefore an important
outcome measure. When compared to placebo, the mean weight
of the danazol group was significantly greater than that of the
placebo group after two months treatment. Three studies assessed
weight gain for danazol compared with a progestogen. The mean
weight gain of the danazol group was significantly greater than
that of the progestogen group. However when weight gain was
assessed in terms of the number of women with a weight gain of
> 2kg (Higham 1993) and the number of women with a weight
gain of >3kg (Bonduelle 1991), there was no significant difference
between the two interventions. There was no significant difference
in terms of the number of women with weight gain of >2kg when
danazol 200mg was compared with a reducing dose of danazol.
However assessment of weight gain by a dichotomous outcome
may not be sensitive to determine real differences between the
groups.One study comparedmeanweight gain for danazol 200mg
versus 100 mg. There appears to be no difference in terms of mean
weight gain between these regimens, however there is currently
insufficient evidence to answer this question.
WITHDRAWALS DUE TO SIDE EFFECTS
There was no significant difference in withdrawals due to side ef-
fects when danazol 200 mg daily was compared to placebo, pro-
gestogens or a reducing dose danazol. However, due to the small
number of women involved in the studies, there is insufficient
evidence to evaluate this outcome adequately. It may be that the
numbers are too small to reveal any differences between the groups.
The large drop out rates of several trials (five studies had drop out
rates of more than 10%) points towards the treatment being unac-
ceptable to women. Some of these may be unreported withdrawals
due to side effects.
DYSMENORRHOEA
There was no significant difference between danazol 200 mg/day,
NSAIDs and a reducing dose of danazol in terms of the number
of women reporting an improvement in dysmenorrhoea. There is
insufficient evidence to determine whether there is any difference
between danazol and progestogens with regards to improvement
in dysmenorrhoea. One study has evaluated this, and the results
indicate that progestogens may produce a greater improvement in
dysmenorrhoea (Bonduelle 1991).
DURATION OF MENSES
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A significant reduction in the duration of menses in favour of
danazol is shown for those trials comparing danazol with NSAIDs
and a progesterone releasing IUD. The results of one trial indicate
that the duration of menses may be shorter after treatment with
a 200mg danazol regimen when compared with a 100 mg regi-
men. Another study showed that the duration of menses is signif-
icantly shorter for women treated with a reducing dose of danazol
compared to those treated with danazol 200 mg/day. There is no
significant difference in the duration of menses when danazol is
compared to progestogens. The results from one trial comparing
danazol with a progestogen, indicate that danazol may cause sub-
stantially more protracted bleeding in some women, whereas this
is not the case for norethisterone (Higham 1993). The reason for
this is unknown.
EFFICACY OF INTERVENTION
Two studies comparing danazol with a progestogen evaluated sub-
jective efficacy of treatment. One study showed subjective efficacy
was significantly greater for danazol, where as the second found
no difference between the two interventions.
ACCEPTABILITY OF INTERVENTION
One study comparing danazol and mefenamic acid assessed the
acceptability of treatment , and found there was no difference
between the two treatments in terms of the number of women
unwilling to continue treatment. However, it may be that too few
participants were included in the analysis to show any difference
between the groups. The study reported that the reason women
were unwilling to continue treatment differed between the two
groups. For the mefenamic acid group, the reason most women
gave for being unwilling to continue treatment was due to a lack
of efficacy, whereas for women in the danazol group it was largely
due to side effects (Dockeray 1989).
DOSAGE
One of the objectives of this review is to determine the optimum
dosage of danazol as a treatment for HMB. Two small trials com-
pared the standard dose of danazol for HMB, 200 mg/day with
a lower dose of 100 mg and a reducing dose regimen. No differ-
ences in effectiveness or frequency of adverse events were reported,
but women treated with 200 mg/day had a shorter duration of
menses when compared with a reducing dose regimen. Numbers
of women in the trials were insufficient to adequately assess this
outcome.
It is important to note that there are no studies comparing danazol
with tranexamic acid and the levonorgestrel-releasing intrauterine
system (Mirena). These treatments may be as effective as danazol,
but an objective comparison has not been carried out.
No study has included changes in quality of life or resource cost as
outcome measures. Danazol has a contraceptive effect in doses of
above 200mg/day, however it is not licensed for use as a contracep-
tive, and therefore women not wishing to conceive require addi-
tional contraception. This is particularly important with danazol
as it is has a teratogenic effect and there is a risk of masculinisation
of a female fetus if exposure to danazol is continued between 8
and 18 weeks of gestation. This means that the acceptability of
danazol to women, and quality of life outcomes are very important
and they have not been properly addressed by any of the trials.
SUMMARY OF THESE RESULTS IN TERMS OF THE OB-
JECTIVES
1. Is danazol more effective than placebo in reducing heavy men-
strual blood loss?
One small trial assessed this outcome, and danazol appears to be
more effective than placebo, but the data are poorly reported.
2. Is danazol more effective than other medical therapies?
Danazol is more effective than progestogens, NSAIDs and the
OCP, although the results are imprecise with wide confidence in-
tervals.
3. What is the optimum dosage of danazol?
The standard dose of 200 mg/day of danazol does not appear
to differ in effectiveness and frequency of adverse events when
compared to 100 mg/day or a reducing regimen. However these
results are based on one small trial for each comparison.
4. Does treatment with danazol lead to an improved quality of life
for women with HMB?
The included trials only assessed improvement in dysmenorrhoea
and therewere insufficient data to address this outcome adequately.
5. Do women tolerate treatment with danazol and find it accept-
able?
There was an increased frequency of adverse events when danazol
was comparedwith othermedical therapies. This did not appear to
affect the acceptability of the treatment. However this comparison
was only reported by one small study.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results do not give clear indications for recommending dana-
zol as a treatment for heavymenstrual bleeding.Danazol appears to
be an effective treatment for heavy menstrual bleeding when com-
pared to other medical treatments, though it is uncertain whether
it is acceptable to women. The use of danazol may be limited by
its side effect profile, its acceptability to women and the need for
continuing treatment.
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Implications for research
Additional well designed RCTs with sufficient power are needed
to test the efficacy of danazol compared to other medical therapies.
Future trial design needs to include outcomes such as quality of
life measures and a longer period of treatment (at least six months)
to adequately evaluate adverse events and participant satisfaction.
However, there may be difficulties in doing long term research
because of the side effects of danazol and the existence of more
acceptable alternatives.
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